Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial

Article Critical Care Medicine

Thromboprophylaxis in Patients With COVID-19 A Brief Update to the CHEST Guideline and Expert Panel Report

Lisa K. Moores et al.

Summary: This article provides updated guidance on thromboprophylaxis for hospitalized COVID-19 patients. The authors offer separate recommendations for patients with acute (moderate) illness and critically ill patients in the ICU. They also address the questions of standard prophylaxis vs therapeutic prophylaxis and standard prophylaxis vs intermediate dose prophylaxis, resulting in modifications to the recommendations based on higher quality evidence.

CHEST (2022)

Add to Collection

Article Hematology

Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial

Farid Rashidi et al.

THROMBOSIS RESEARCH (2022)

Add to Collection

Article Critical Care Medicine

Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19 A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial

Christopher D. Barrett et al.

Summary: This study investigated the effects of tissue plasminogen activator (tPA) on pulmonary function in severe COVID-19 respiratory failure. The results showed significant improvement in lung oxygenation in the tPA bolus group compared to the control group. However, there were no statistically significant differences in the improvement of PaO2/FIO2 ratio, composite outcome, ventilator-free days, and in-hospital mortality between the tPA bolus group and the control group.

CHEST (2022)

Add to Collection

Article Hematology

Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial

Marc Blondon et al.

Summary: This study aimed to test whether therapeutic anticoagulation improves clinical outcomes in severe COVID-19 patients. The results showed that among critically ill patients receiving corticosteroids and with exclusion of pulmonary embolism at hospital admission, risks of mortality, thrombotic outcomes, and DIC were low at 30 days. The lack of benefit of therapeutic anticoagulation was inconclusive.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Ewan C. Goligher et al.

Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Critical Care Medicine